We are a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of market-leading products in certain orphan and other well-defined, high-margin specialty markets.
|Feb02||SteadyMed to Present at 18th Annual BIO CEO & Investor Conference|
|Jan06||Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European Medicines Agency|
|Jan05||SteadyMed Receives Orphan Drug Designation for Trevyent for the Treatment of Pulmonary Arterial Hypertension|
In June, SteadyMed's Jonathan Rigby biked from London to Paris in support of PH. The 299 mile, 4 day route traveled through English countryside, to the ferry from Dover to Calais. Once 'French side', the riders pushed on cycling along French country lanes, finishing the nearly 300 mile trek at the Eiffel Tower. If you would like to learn more about the event, or are interested in supporting Jonathan and the PH Community, please follow this link.